Evolent Health, Inc. EVH R2KR3KPHARMA
Company Overview
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Why Investors Should Care
Revenue has grown at a 24.9% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.88B (-26.6% YoY); net profit $-534.51M.
- Trailing 12 Months Year-on-year growth — revenue +46.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 24.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 24.87% |
| 1 Year: | 46.90% |
Stock Price Performance
| 1 Year: | -46.49% |
| 6 Months: | +53.35% |
| 3 Months: | +25.98% |
| 1 Month: | +36.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 24.9% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 52.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EVH Evolent Health, Inc. R2KR3KPHARMA | 4.80 | -1.07 | $542.68M | 0.00% | -27.09% | -66.97% | 24.87% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 106.24M | 107.07M | 107.91M | 113.73M | 139.71M | 144.30M | 149.95M | 193.10M | 197.76M | 191.96M | 220.14M | 236.53M | 247.28M | 238.63M | 264.59M | 271.92M | 215.07M | 222.06M | 222.47M | 297.06M | 319.94M | 352.58M | - | 427.69M | 469.14M | 511.01M | 556.05M | 639.65M | 647.14M | 621.40M | 646.54M | 483.65M | 444.33M | 479.53M | 468.72M | 496.25M | 652.52M |
| Operating Income | -12.63M | -15.84M | - | -21.45M | -19.12M | -14.02M | - | -14.13M | -8.97M | -11.03M | - | -46.65M | -25.23M | -20.14M | - | -25.09M | -225.83M | -16.45M | - | -15.95M | -7.67M | -6.58M | -2.80M | -4.63M | 12.95M | - | -10.36M | -21.57M | -17.94M | - | -13.41M | 7.79M | -16.27M | - | -1.62M | -1.17M | 886.00K | - | -10.60M | -9.56M |
| Net Income | -8.39M | -11.21M | -17.41M | -18.01M | -16.91M | -12.59M | -13.16M | -13.63M | -9.92M | -12.43M | -16.69M | -46.74M | -31.61M | -25.52M | -198.10M | -78.75M | -203.52M | -37.35M | -14.62M | -9.81M | -9.11M | -13.04M | -5.35M | -4.59M | 2.12M | - | -19.98M | -34.32M | -25.32M | -33.41M | -17.28M | 1.60M | -23.14M | -22.80M | -64.62M | -19.90M | -20.86M | -429.13M | -26.63M | -28.36M |
| Diluted EPS | -0.20 | -0.26 | -0.33 | -0.34 | -0.28 | -0.18 | -0.18 | -0.18 | -0.13 | -0.16 | - | -0.59 | -0.38 | -0.30 | - | -0.93 | -2.38 | -0.44 | - | -0.12 | -0.11 | -0.15 | -0.06 | -0.05 | 0.02 | -0.11 | -0.24 | -0.37 | -0.30 | -0.36 | -0.22 | -0.06 | -0.27 | -0.27 | -0.63 | -0.44 | -0.24 | -3.84 | -0.24 | -0.25 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.40M | - | 4.20M | 4.10M | 3.80M | 3.80M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 254.19M | 434.95M | 627.06M | 846.38M | 924.64M | 907.96M | 1.35B | 1.96B | 2.55B | 1.88B |
| Operating Income | -21.16M | 0 | -42.97M | -237.42M | -72.84M | -47.48M | -308.88M | -262.85M | -42.41M | 3.64M | -71.21M | -40.48M | -410.14M |
| Net Income | 20.02M | -25.25M | 332.49M | -159.74M | -60.66M | -52.66M | -301.97M | -334.25M | -37.60M | -19.16M | -113.04M | -61.62M | -534.51M |
| Diluted EPS | 0.99 | -13.46 | 6.93 | -3.55 | -0.94 | - | -3.67 | -3.94 | -0.44 | -0.20 | -1.28 | -0.81 | -5.07 |
| R&D Expense | 2.00M | 0 | 5.80M | 11.10M | 17.20M | 18.20M | 19.80M | 15.10M | 15.50M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 37.20M | 1.02B | 1.20B | 1.31B | 1.72B | 1.50B | 1.37B | 1.42B | 1.82B | 2.68B | 2.54B | 1.90B |
| Total Equity | 5.20M | 13.26M | -2.07M | 649.34M | 702.53M | 1.01B | 1.14B | 929.05M | 619.60M | 693.63M | 859.42M | 1.07B | 1.00B | 415.19M |
| Cash & Equivalents | 5.25M | 0 | 0 | 145.73M | 134.56M | 238.43M | 228.32M | 101.01M | 319.00M | 266.28M | 188.20M | 192.82M | 104.20M | 151.86M |
| Long Term Debt | - | - | - | 0 | 120.28M | 121.39M | 221.04M | 293.67M | 263.34M | 215.68M | 412.99M | 597.05M | 490.52M | 970.54M |
| Total Liabilities | - | - | 0 | 80.94M | 287.73M | 266.39M | 532.92M | 568.97M | 752.10M | 725.83M | 957.88M | 1.43B | 1.35B | 1.48B |
| Current Liabilities | - | - | 0 | 59.51M | 131.94M | 132.70M | 269.36M | 192.77M | 403.29M | 445.49M | 433.44M | 674.24M | 715.50M | 385.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.63M | 0 | -18.47M | -35.51M | -27.96M | -20.65M | -42.65M | -16.23M | 38.75M | -11.55M | 142.58M | 18.77M | 38.84M |
| Investing Cash Flow | -25.91M | 0 | -43.68M | -96.66M | -12.27M | -160.38M | -181.63M | 261.07M | -15.79M | -259.12M | -415.54M | -62.93M | -233.00K |
| Financing Cash Flow | 34.29M | 0 | 214.16M | 150.19M | 165.56M | 274.02M | -35.55M | -11.86M | -29.55M | 131.54M | 281.34M | -565.00K | -35.92M |
| Capital Expenditure | -10.44M | -0 | -6.51M | -15.53M | -27.85M | -39.55M | -35.53M | - | - | - | - | - | - |
| Free Cash Flow | -24.07M | 0 | -24.98M | -51.04M | -55.81M | -60.20M | -78.18M | - | - | - | - | - | - |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 40.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -93.4% | -16.7% | -7.6% | -36.5% | -28.4% | -4.7% | 0.3% | -3.6% | -1.6% | -21.9% |
| Net Margin % | - | - | - | -62.8% | -13.9% | -8.4% | -35.7% | -36.1% | -4.1% | -1.4% | -5.8% | -2.4% | -28.5% |
| ROE % | 151.0% | 1,219.6% | 51.2% | -22.7% | -6.0% | -4.6% | -32.5% | -53.9% | -5.4% | -2.2% | -10.6% | -6.2% | -128.7% |
| ROCE % | - | 0.0% | -4.5% | -22.2% | -6.2% | -3.3% | -23.7% | -27.1% | -4.4% | 0.3% | -3.5% | -2.2% | -27.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.10% | 14.81M | $59.85M |
| 2 | Cadian Capital Management, LP | 9.57% | 10.81M | $43.69M |
| 3 | Morgan Stanley | 7.93% | 8.97M | $36.23M |
| 4 | UBS Group AG | 5.52% | 6.25M | $25.23M |
| 5 | Rubicon Founders LLC | 5.14% | 5.82M | $23.50M |
| 6 | Engaged Capital, LLC | 4.92% | 5.56M | $22.48M |
| 7 | Shaw D.E. & Co., Inc. | 4.52% | 5.11M | $20.63M |
| 8 | Vanguard Capital Management LLC | 4.23% | 4.79M | $19.34M |
| 9 | Marshall Wace LLP | 3.02% | 3.41M | $13.79M |
| 10 | Nuveen, LLC | 2.77% | 3.13M | $12.65M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EVH
Why Evolent Health (EVH) Stock Is Nosediving - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQbUl0WjJtZUppVTFsSWJ4Yk42OW1KR0IyMXZld2dPMkxiLWlUdGREdzM1MF9HWnlZMFhWM3dzQlVxdVJwQ1lSYWZGemhMQXUtZ0wwWnA1c1lRWGd0YmhJN2lCX25nd1NSS19pcjBRWGdEanluY210bms2ekpZV0NRT1NOT3A4RjZCYWNQel…
Evolent Health(EVH) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMioANBVV95cUxQR2ktTWpnLUtFOXdUU1A4cEZXQzhDMGs5dUdVTGtSYkYxWHBDZ3JpSU1pTWJuQ1FwY1c0Qm5qa1RoNTNtZzVnajhucW44TE1QWHZVOFNyREoxVXpsaFBTNjctRFJPRGZqMnhjVzZtMUJrOHd0VUZ5a0p0TTkxNm1OUGxPbGZXdnhHNlZoc0…
EVH Stock On Track To Open At Record Low – Here’s Why Keybanc Turned Cautious - Stocktwits
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPeGFiME5wdzJ6UENWM0NvYXkwS1dQVnUyVUE4ZmhUZjlDSVZ6UkhPWlBuTUV0R0NsOW52NGhJOVg2ZllaTzI2Tl8tUTZDMDdRODYybU0xWmlxQU5lTHZyT1F3NmJINEQ5QzdlZ1VneXdCbzNzWFNvZmI3ZDlfUDY1ellDb0JvR3diNjk0MW…
Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming (EVH) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNM1FUUFllT0ljMDRnRUxnanhJaThxN3FIYmJ1Zk1KdXUwMnU1RUJHU3c3WEt3VktqM0dub3lqZWZQdG50a24waFhGZGF2WEV0Q3VXaUV4X0tNRlBGRUQ4czJReWxkSjNzMmpiQ21QVUNaSmVqRVhlSEh4Wm5oQVVOYXRyZzRPbnd3OHY0TF…
EVH Jan 2027 17.500 call (EVH270115C00017500) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE1oRzNrSWhnb0F4S0RyVmEtZXZhWGptRkdubzRJVm13TnRhRUhIVDdzQm1GTlZuOERPMDRJUXVqZTJsWnl3RGd5VHl6aVMwc0luT2V1b2R0LURWUlMzRHVNLWkyTk9jQ3l2bER3cFBaMEZLdw?oc=5" target="_blank">EVH Jan 2027 …
Canaccord cuts Evolent Health stock price target on margin outlook - Investing.com
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxONV9wVlNKeDVwamVYRk5JRmljdlJqaFNJNmZVOXBFNVJBZkhIMG9MY2c5ZXVlUmxKXzdyYzlSM2F2OG1OVlV1SHdRdVZwdkc4QVppZjJUS0I2YWxVRTRDQkZzaVJqOTR4ZVBhXzJjb3QzdkdlRHNaNEE4d3phOXFIYzdUSDJpR1l5V2JmSk…
EVH — Frequently Asked Questions
What is the current share price of Evolent Health, Inc. (EVH)?
As of 2026-10-23 16:27 PDT, Evolent Health, Inc. (EVH) trades at $4.80 on NYSE. Its 52-week range is $2.17 to $9.99.
What is the market capitalisation of EVH?
Evolent Health, Inc. (EVH) has a market capitalisation of $542.68M on NYSE.
What is the P/E ratio of EVH?
EVH trades at a trailing price-to-earnings (P/E) ratio of -1.07. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.19.
What is the return on equity (ROE) of EVH?
EVH has a return on equity (ROE) of -66.97%. Its return on capital employed (ROCE) is -27.09%.
Is EVH a good stock to buy?
This page provides a data-driven analysis of Evolent Health, Inc. (EVH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.